Stocks · News reference

Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Aug 20, 2026, 4:47 PMBenzinga Newsdesk

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 20, 2026, 6:08 AMBenzinga Newsdesk
Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M
Read original at benzinga
TLX
BenzingaAug 20, 2026, 6:04 AMBenzinga Newsdesk
Reported Earlier, Telix Pharmaceuticals Reports H1 2026 Revenue Of $477M, Up 22% YoY, And Profit After Tax Of $38M Versus $2M Loss
Read original at benzinga
TLX
Globenewswire IncJul 30, 2026, 10:37 PMTelix Pharmaceuticals Limited
Telix H1 2026 Results: Investor Webcast Notification
Telix Pharmaceuticals announced it will release its half-year financial results for June 30, 2026 on August 20, 2026, with an accompanying investor webcast and conference call. The company reported Q2 2026 revenue of US$247M with strong commercial momentum and pipeline progress across its radiopharmaceutical portfolio.
Read original at globenewswire-inc
TLX